SCHEMBL5013555

SCHEMBL5013555

O=C(O)c1sc2c(nc(-c3ccccc3)n2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
HTT P42858 1/20 0.41
CYP2C19 P33261 3/20 0.41
CYP2C9 P11712 2/20 0.41
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
MDM2 Q00987 1/20 0.40
KDM4E B2RXH2 3/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 2/20 0.38
HCAR1 Q9BXC0 1/20 0.37
ALDH1A1 P00352 3/20 0.36
GSK3B P49841 1/20 0.36
PDE7A Q13946 1/20 0.36
PDE7B Q9NP56 1/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 1/20 0.36
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5015628 0.86 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP2C19CYP2C9PI4KA
SCHEMBL5013552 0.78 OPRM1 (0.39) SMN1; SMN2CYP2C19CYP2C9KDM4E
SCHEMBL5014020 0.71 KDM4E (0.48) SMN1; SMN2HTTMDM2KDM4EHCAR1
SCHEMBL5650705 0.71 KMT2A (0.43) SMN1; SMN2CYP2C19CYP2C9KDM4ELMNA
SCHEMBL69825 0.68 GRIA4 (0.50) SMN1; SMN2HTTCYP2C19CYP2C9KDM4E
SCHEMBL5782959 0.67 MDM2 (0.54) SMN1; SMN2HTTMDM2TSHRHCAR1
SCHEMBL28979811 0.67 PI4KA (0.48) SMN1; SMN2HTTCYP2C19CYP2C9PI4KA
SCHEMBL18493217 0.67 PI4KA (0.54) SMN1; SMN2HTTCYP2C19PI4KAPI4K2B
SCHEMBL5012193 0.66 MDM2 (0.43) SMN1; SMN2HTTMDM2KDM4ETSHR
SCHEMBL5015627 0.65 GAA (0.40) SMN1; SMN2HTTCYP2C19CYP2C9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249146-A1 Imidazole and Thioazole Derivatives as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-10-09 US claimed
US-20080255038-A1 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin SCYNEXIS, INC. 2008-10-16 US disclosed
US-20080249146-A1 Imidazole and Thioazole Derivatives as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-10-09 US disclosed
US-20080249146-A1 Imidazole and Thioazole Derivatives as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-10-09 US disclosed
US-20080249146-A1 Imidazole and Thioazole Derivatives as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255038-A1 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin NSUN2, TPMT, EIF5B SMN1; SMN2 2367/4885HTT 3034/4885CYP2C19 377/4885
US-20080249146-A1 Imidazole and Thioazole Derivatives as Antiviral Agents IRF3, HAVCR2, ZC3HAV1 SMN1; SMN2 4641/4885HTT 4249/4885CYP2C19 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.